Abstract
Abstract Background and aims: The epidemic of diabetes mellitus has made the effective treatment of hyperglycemia a top priority. Maintaining near-normal glycemic levels has been demonstrated to have a beneficial effect on diabetes-specific complications. Insulin can decrease any level of elevated glycated hemoglobin. Insulin glargine (Lantus®) is a long-acting insulin analog with a favorable 24-h time-action profile, once daily administration and low risk of hypoglycemia used in type 1 and 2 diabetes. In Romania, real-life data about glycaemic control is lacking. Material and methods: We present results from a retrospective, open-label, non-randomised, registry trial in 2946 Romanian diabetes patients. The objective of the study was to assess the proportion of patients with appropriate glycaemic control after 3 to 6 months of glargine treatment. Results and conclusions: A little over one third of the patients had reached target glycated hemoglobin after 3-6 months of glargine treatment in both types of diabetes. In type 2 diabetes patients the glargine dose used was not high (0.33 UI/kg). Inadequate insulin titration is a possible cause for not reaching glycemic targets.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Romanian Journal of Diabetes Nutrition and Metabolic Diseases
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
